CD73 as a potential opportunity for cancer immunotherapy
Ghasem Ghalamfarsa(Yasuj University of Medical Sciences), Farhad Jadidi‐Niaragh(Tabriz University of Medical Sciences), Mehdi Yousefi(Tabriz University of Medical Sciences), Gholamreza Azizi(Jefferson Hospital for Neuroscience), Ali Masjedi(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Mohammad Hossein Kazemi(University of Southern California), Sahar Raoofi Mohseni(Tehran University of Medical Sciences)
Cited by 143
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
|International Immunopharmacology|2022|384
Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment
|Frontiers in Immunology|2022|363
Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management
|Scandinavian Journal of Immunology|2020|339
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312